“…Overexpression of MYOF has been associated with many cancers in humans, including breast cancer, lung cancer, and pancreatic cancer, and is shown to promote tumorigenesis, tumor cell motility, proliferation, migration, and metastasis [32][33][34]. Furthermore, other studies had reported up-regulation or down-regulation of TMEM156, ELOVL5, KIF23, AMPD3, CCNB1, CENPE, UBE2C, NXPE3, and PDE4DIP to be associated with numerous types of cancers in humans, such as breast cancer, ovarian cancer, non-small cell lung cancer, clear cell renal cell carcinoma, stomach cancer, colorectal cancer, esophageal cancer, pancreatic cancer, hepatocellular cancer, lung cancer, and prostate cancer [35][36][37][38][39][40][41][42][43][44][45]. Our results were consistent with the previous findings that indicated DEGs to possibly have great implication in tumor/cancer progression.…”